A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines
David Durrant, Anindita Das, Samya K. Dyer, Rakesh C. Kukreja
Topics & Concepts
PI3K/AKT/mTOR pathwayDoxorubicinIntracellularOvarian cancerCancer researchPancreatic cancerProtein kinase BPharmacologyCancer cellDrug resistanceViability assayPARP inhibitorMultiple drug resistanceCell cultureChemistryBiologyCancerApoptosisMedicineChemotherapyCell biologyInternal medicineBiochemistryPoly ADP ribose polymeraseEnzymePolymeraseGeneticsMicrobiologyDrug Transport and Resistance MechanismsPI3K/AKT/mTOR signaling in cancerCancer, Lipids, and Metabolism